Vulcan Energy gets $106 million funding from German ministry
Shares of Vulcan Energy surged as much as 16.8% to a more than 18-month high on Tuesday.
(via TheNewswire)
(Richmond Hill, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce that it has successfully closed its Early Warrant Exercise Incentive Program (the “Incentive Program”) and Extension of Warrant Exercise Period (“Warrant Extension”), previously announced on March 11, 2022 and April 13, 2022. The Company has received gross proceeds of $3,210,204 from the exercise of 12,346,938 share purchase warrants at $0.26 per share.
The balance of the warrants not exercised under this Incentive Program and Warrant Extension will remain outstanding and continue to be exercisable for common shares of the Company on their original terms.
The proceeds from the Incentive Program and Warrant Extension will be used for working capital purposes and advancing the Company’s L-DOS47 drug development program.
Artur Gabor, CEO of Helix, stated “We are extremely grateful for the support and belief in the Company from the warrant holders that participated in our Early Warrant Exercise Incentive Program and Warrant Extension. This is significant as it demonstrates their belief in the Company and the technology. With the capital raised, we are financially well situated for operations for our development programs.”
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the TSX under the symbol “HBP”.
For more information, please contact:
Helix BioPharma Corp.
9120 Leslie Street, Suite 205 Richmond Hill, Ontario, L4B 3J9 Tel: 905-841-2300
Namrata Malhotra, Corporate Secretary
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to DOS47, and statements regarding expected improvements to the Company’s independence, diversification and corporate governance and the Company’s expectations regarding strengthening its future growth capabilities. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.
Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward- looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management’s current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release.
The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation; the risk that the Company’s assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company’s research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company’s anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company’s annual management’s discussion and analysis for the year ended July 31, 2021 under the heading “Risks and Uncertainties” and Helix’s Annual Information Form, in particular under the headings “Forward-looking Statements” and “Risk Factors”, and other reports filed under the Company’s profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.
